Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aptose Biosciences Inc | APTO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.22 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.20 - 8.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.22 | USD |
Aptose Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
502.35M | 7.54M | - | 0 | -51.21M | -6.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aptose Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APTO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.25 | 1.29 | 1.20 | 1.23 | 42,414 | -0.03 | -2.40% |
1 Month | 1.50 | 1.7203 | 1.20 | 1.43 | 76,461 | -0.28 | -18.67% |
3 Months | 2.09 | 2.20 | 1.20 | 1.68 | 79,994 | -0.87 | -41.63% |
6 Months | 2.60 | 3.32 | 1.20 | 2.01 | 75,952 | -1.38 | -53.08% |
1 Year | 7.353 | 8.70 | 1.20 | 4.38 | 91,010 | -6.13 | -83.41% |
3 Years | 76.50 | 87.60 | 1.20 | 30.62 | 437,816 | -75.28 | -98.41% |
5 Years | 28.05 | 138.7875 | 1.20 | 64.39 | 778,417 | -26.83 | -95.65% |
Aptose Biosciences Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. |